A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease

Dry Eye Disease Clinical Trial

— REDUCO  

Official title:

A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at Two Different Concentrations in Patients With Dry Eye Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06244316
• Other study ID #: NGF0123
• Status: Recruiting
• Phase: Phase 2
• Start date: January 22, 2024
• Est. completion date: September 2024

Study information

• Verified date: April 2024
• Source: Dompé Farmaceutici S.p.A
• Contact: Marta Sacchetti, MD
• Phone: +39 34 76757333
• Email: marta.sacchetti[@]dompe.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of two different concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least one of the two concentrations over vehicle in the improvement of ocular symptoms of dry eye in participants with dry eye disease (DED). The rhNGF ophthalmic solution, or vehicle, will be administered as one drop in each eye, three times a day, for 4 weeks. Participants will attend a total of 5 study visits from screening through end of the study (Week 8), which will include eye exams and questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 291
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female aged =18 years of any race/ethnicity and eye color.

• A diagnosis of dry eye disease at least 6 months before enrollment (current use or recommended use of artificial tears for the treatment of dry eye).

• Moderate-to-severe dry eye characterized by the following clinical features:

1. Symptoms Assessment in Dry Eye (SANDE) questionnaire global score =50, and

2. Schirmer-I test without anesthesia >2 mm and <10 mm/5 minutes, and

3. Total corneal fluorescein staining grade =3 (NEI scale) and/or total conjunctival lissamine green staining score =3 assessed by the NEI grading system, and

4. Fluorescein tear film break-up time (fTBUT) < 10 seconds The same eye must have fulfilled all the above criteria.

• Best corrected distance visual acuity (BCDVA) score on ETDRS chart of =0.1 decimal units (=1.0 logMAR) in each eye at the time of study enrollment

• Negative pregnancy test in females of childbearing potential.

• Only participants who satisfy all informed consent requirements will be included in the study; the participant and/or his/her legal representative must have read, signed, and dated the informed consent document before any study-related procedures are performed; the informed consent form signed by participants and/or legal representatives must have been approved by the Institutional Review Board (IRB) for the current study.

• Have the ability and willingness to comply with study procedures.

Exclusion Criteria:

• Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.

• Evidence of an active ocular infection in either eye.

• Presence of any other ocular disorder or condition requiring topical ocular medication during the entire duration of the study.

• History of severe systemic allergy or severe ocular allergy [including seasonal conjunctivitis, AKC (Atopic KeratoConjunctivitis), VKC (Vernal KeratoConjunctivitis)] or chronic conjunctivitis and/or keratitis other than dry eye.

• Ocular scarring due to irradiation, alkali burns, Stevens-Johnson syndrome and ocular cicatricial pemphigoid.

• Destruction of conjunctival goblet cells such as in Vitamin A deficiency.

• Severe blepharitis or obvious inflammation of the lid margin.

• Intraocular inflammation defined as Tyndall score >0.

• Medical history of tumor malignancy in the previous 3 years

• Systemic disease not stabilized within 1 month before the screening visit (e.g., diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (e.g., current systemic infections) or with a condition incompatible with the frequent assessment required by the study.

• History of a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or had a clinically significant allergy to drugs, foods, topical anesthetic eye drop or other local anesthetics or other materials, including ocular vital dyes, tropicamide eye drops, commercial artificial tears.

• Known or suspected allergy to component(s) of the new rhNGF formulation.

• Fertile patients (i.e., not surgically sterilized, or postmenopausal women for at least 1 year) are excluded from participation in the study if they do not practice abstinence from heterosexual intercourse as per usual and customary lifestyle, or are unwilling to use an acceptable form of contraception such as condom with spermicidal cream or jelly for males, or for females if they meet any one of the following conditions:

1. Currently pregnant (positive urine pregnancy test at screening or baseline visits) or planning to become pregnant during the duration of the treatment phase of the clinical trial.

2. Participant is breastfeeding.

3. Unwilling to use birth control measures such as mechanical barrier methods (spermicide in conjunction with a barrier such as a condom or diaphragm or intrauterine device) during the entire course of and 30 days after the study treatment period, or,

4. Unwilling to continue to use highly effective birth control measures such as hormonal contraceptives (oral, implanted, transdermal, or injected) during the entire course of and 30 days after the study treatment period.

• Any concurrent medical condition that, in the judgment of the principal investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the participant's well-being.

• Contact lenses or punctum plug use in either eye during the washout, treatment, and follow-up phases of the study (previous use is not an exclusion criteria but must be removed and discontinued at the Screening visit).

• Medical history of drug addiction or alcohol abuse (>1 drink /day for women and >2 drinks /day for men following USDA dietary Guidelines 2020-2025).

• Any prior ocular surgery including but not limited to amniotic membrane transplant, refractive [PTK (Excimer Laser Phototherapeutic Keratectomy) / LASIK (Laser-Assisted In Situ Keratomileusis) / Epi-LASIK (Epithelial Laser In Situ Keratomileusis) / LASEK (Laser-Assisted Subepithelial Keratectomy) / SMILE (Small Incision Lenticule Extraction)], palpebral, cataract surgery, trabeculectomy, vitrectomy and Pan-Retinal Photocoagulation (PRP) within 90 days before the screening visit.

• Participation in a clinical trial with a new active substance, including medical devices, during the previous 60 days.

• Participation in another clinical trial study at the same time as the present study.

Related Conditions & MeSH terms

• Dry Eye Disease
• Dry Eye Syndromes
• Eye Diseases
• Keratoconjunctivitis Sicca

Intervention

Drug:
• rhNGF concentration 1
Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
• rhNGF concentration 2
Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
• Vehicle (Placebo solution)
Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera Universitaria Policlinico G Martino	Messina
Italy	Ospedale S. Giuseppe Multimedica	Milano
Italy	Azienda Ospedaliero Universitario Policlinicol Umberto I	Roma
Italy	Fondazione Policlinico Universitario Campus Bio-Medico di Roma	Roma
United States	Eye Consultants of Atlanta	Atlanta	Georgia
United States	New England Eye Center - Boston	Boston	Massachusetts
United States	Sibia Eye Institute	Boynton Beach	Florida
United States	Arizona Eye Center	Chandler	Arizona
United States	Vision Institute - Fontanero St	Colorado Springs	Colorado
United States	Eye Associates of North Jersey	Dover	New Jersey
United States	Total Eye Care PA	Memphis	Tennessee
United States	Toyos Clinic	Nashville	Tennessee
United States	The Scheie Eye Institute	Philadelphia	Pennsylvania
United States	East West Eye Institute	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Dompé Farmaceutici S.p.A

Countries where clinical trial is conducted

United States,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline to Week 8 in symptoms of dry eye assessed by SANDE Global Score	Symptom Assessment in Dry Eye (SANDE) scores range from 0 to 100, with 100 representing the most frequent and severe dry eye symptoms.	Week 8
Secondary	Mean change from baseline in Schirmer- I score without anesthesia in the Study Eye	Schirmer-I test will be performed without anesthesia to determine wetting of the strip within 5 minutes and the length of the moistened strip will be measured in millimeters (mm).	Week 4
Secondary	Mean change from baseline in total corneal fluorescein staining (National Eye Institute NEI scale) in the Study Eye as assessed by the investigator	Corneal fluorescein staining NEI score ranges from 0 to 15, with a higher number representing more staining.	Week 4
Secondary	Mean change from baseline in ocular pain assessed by the OPAS questionnaire's pain scale	The Ocular Pain Assessment Survey (OPAS) questionnaire scores range from 0 - 10 with a higher score representing more disruption due to eye pain.	Week 4
Secondary	Mean change from baseline in Schirmer- I score without anesthesia in the Study Eye	Schirmer-I test will be performed without anesthesia to determine wetting of the strip within 5 minutes and the length of the moistened strip will be measured in millimeters (mm).	Week 8
Secondary	Proportion of participants improving to Schirmer-I test without anesthesia = 10 mm/5min in the Study Eye	Schirmer-I test will be performed without anesthesia to determine wetting of the strip within 5 minutes and the length of the moistened strip will be measured in millimeters (mm).	Week 4
Secondary	Proportion of participants improving to Schirmer-I test without anesthesia = 10 mm/5min in the Study Eye	Schirmer-I test will be performed without anesthesia to determine wetting of the strip within 5 minutes and the length of the moistened strip will be measured in millimeters (mm).	Week 8
Secondary	Mean change from baseline in fluorescein tear break-up time (fTBUT)- in Study Eye	Fluorescein tear break-up time (fTBUT) is the time to tear film break-up, in seconds, taken 2 or 3 times. The fTBUT value is the average of the 2 or 3 measurements.	Week 4
Secondary	Mean change from baseline in fluorescein tear break-up time (fTBUT)- in Study Eye	Fluorescein tear break-up time (fTBUT) is the time to tear film break-up, in seconds, taken 2 or 3 times. The fTBUT value is the average of the 2 or 3 measurements.	Week 8
Secondary	Mean change from baseline in total conjunctival lissamine green staining (NEI scale) in Study Eye as assessed by the investigator	Lissamine green conjunctival staining NEI score ranges from 0 to 18, with a higher number representing more staining.	Week 4
Secondary	Mean change from baseline in symptoms questionnaire (SANDE) scores for severity and frequency	Symptom Assessment in Dry Eye (SANDE) scores range from 0 to 100, with 100 representing the most frequent and severe dry eye symptoms.	Week 4
Secondary	Mean change from baseline in symptoms questionnaire (SANDE) scores for severity and frequency	Symptom Assessment in Dry Eye (SANDE) scores range from 0 to 100, with 100 representing the most frequent and severe dry eye symptoms.	Week 8
Secondary	Mean change from baseline in symptoms of dry eye assessed by SANDE Global Score	Symptom Assessment in Dry Eye (SANDE) scores range from 0 to 100, with 100 representing the most frequent and severe dry eye symptoms.	Week 4
Secondary	Mean change from baseline in ocular pain assessed by the OPAS questionnaire's pain scale	The Ocular Pain Assessment Survey (OPAS) questionnaire scores range from 0 - 10 with a higher score representing more disruption due to eye pain.	Week 8
Secondary	Mean change from baseline as assessed by the OPAS questionnaire QoL scores	The Ocular Pain Assessment Survey (OPAS) questionnaire scores range from 0 - 10 with a higher score representing more disruption due to eye pain.	Week 4
Secondary	Mean change from baseline as assessed by the OPAS questionnaire QoL scores	The Ocular Pain Assessment Survey (OPAS) questionnaire scores range from 0 - 10 with a higher score representing more disruption due to eye pain.	Week 8
Secondary	Mean change from baseline in BCDVA score	Best Corrected Distance Visual Acuity (BCDVA) score is represented as a fraction with 20 as the numerator and a variable denominator. The higher the denominator, the worse the visual acuity.	Week 4
Secondary	Mean change from baseline in BCDVA score	Best Corrected Distance Visual Acuity (BCDVA) score is represented as a fraction with 20 as the numerator and a variable denominator. The higher the denominator, the worse the visual acuity.	Week 8
Secondary	Incidence and frequency of Treatment-Emergent Adverse Events (TEAEs) assessed throughout the study including Run-In period		Week 8
Secondary	Mean change from baseline in corneal endothelial cell density in both eyes		Week 8
Secondary	Change from baseline in the proportion of participants with vitritis, retinal or vitreal hemorrhages, increase in cup-to-disc ratio, retinal or posterior vitreal detachment, retinal tears, or maculopathy on dilated fundus exam (DFE) in both eyes		Week 8
Secondary	Mean change from baseline in bulbar conjunctival redness (VBR 10 score) in both eyes	The Validated Bulbar Redness (VBR) scale ranges from 10 to 100 with a higher score meaning more severe redness.	Week 4
Secondary	Mean change from baseline in bulbar conjunctival redness (VBR 10 score) in both eyes	The Validated Bulbar Redness (VBR) scale ranges from 10 to 100 with a higher score meaning more severe redness.	Week 8
Secondary	Treatment discontinuation rate due to tolerability		Week 4